Bispecific Antibody Provides Durable Remission in Myeloma
REGN5459, designed to deplete plasma cells while mitigating the cytokine release syndrome, demonstrated deep and durable clinical responses in heavily pretreated relapsed/refractory myeloma.
Dana Farber Cancer Institute United States Attaya Suvannasankha Kenneth Anderson Indiana University Simon Cancer Center Regeneron Pharmaceuticals
Source: medscape.com